Quark Pharmaceuticals, based in Freemont California, have announced preliminary results of a study using a chemically modified siRNA to down regulate a gene known as… Read More »Quark Pharmaceuticals presents results with siRNA for treatment of DMA and wet AMD
Paloma Pharmaceuticals have announced positive results with a small molecule inhibitor of the P13K/Akt/mTOR pathway implicated in a wide variety of biological responses.
Fovea Pharmaceuticals (Paris, France) and Dyax Corporation (Cambridge, Massachusetts, USA) have announced the execution of an exclusive license agreement for the development and commercialisation of… Read More »French and US companies combine efforts on retinal vein occlusion-induced macular edema
test